Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 11, 2024
Finance
Upstream catches aftermarket updraft, as Camp4 IPO gets muted reception
BioCentury’s weekly Public Equity Report also includes financings by Crinetics, Scholar Rock, Immatics, Inhibikase and Vicore
BioCentury | Sep 11, 2023
Deals
Sept. 11 Quick Takes: Surprise miss for Acelyrin in hidradenitis suppurativa
Plus: Moderna, Immatics in oncology discovery, development deal, and updates from Takeda, Novartis, Crinetics, Verona, Nestlé
BioCentury | May 3, 2023
Deals
May 2 Quick Takes: Janssen paying CBMG $245M for CAR T rights
Plus: Delay in Senate for drug pricing votes plus updates from Ten63, FDA, Immatics, Travere, Ascletis and more
BioCentury | Oct 26, 2022
Product Development
GSK exits clinical oncology cell therapies with NY-ESO-1 drops
GSK drops more cancer programs as it steps away from Lyell, Adaptimmune partnerships
BioCentury | Oct 11, 2022
Product Development
Immatics looks to build on momentum for TCR T cell therapy
Company parlays data for PRAME therapy into $110M follow-on
BioCentury | Sep 14, 2022
Product Development
As ESMO data raise doubts about PRAME target, Immunocore also looks to KRAS
Disappointing results for Immunocore’s PRAME-targeted TCR bispecific at ESMO sink shares
BioCentury | Feb 23, 2022
Deals
BioNTech adds to TCR arsenal with Medigene’s PRAME, platforms
The deal includes a switch technology that converts immunosuppressive ligands into costimulatory signals
BioCentury | Jan 27, 2022
Regulation
Immunocore charts path to broader indications, new targets after first FDA approval
Kimmtrak authorization brings the first uveal melanoma therapy and a new immuno-oncology modality to market
BioCentury | Nov 25, 2021
Product Development
Next-gen TILs and TCRs face a durability challenge
SITC provides a snapshot of how companies are enhancing TIL and TCR therapies
BioCentury | Nov 10, 2021
Product Development
Investors seek durability gains for Immatics’ TCR
Get impressive solid tumor response rates instead
Items per page:
1 - 10 of 24